Fig. 1 · Structure

Documents & Downloads

(S)-10-Hydroxycamptothecin

Cat. No. A11997 CAS 19685-09-7

Topoisomerase

(S)-10-Hydroxycamptothecin is a camptothecin derivative that inhibits DNA topoisomerase by enacting strand breaks in chromosomal DNA and inducing apoptosis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
DNA topoisomerase I

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 0.004 μM Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay [PMID: 22959246]
A2780 IC50 0.7 μM Cytotoxicity against human A2780 cells after 48 hrs by MTT assay [PMID: 19715319]
A-375 IC50 0.15 μM Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay [PMID: 23639650]
A-375 IC50 27.8 μM Cytotoxicity against human A375 cells after 72 hrs by MTT assay [PMID: 26280921]
A-375 IC50 27.8 μM Cytotoxicity against human A375 cells after 72 hrs by MTT assay [PMID: 25874331]
A549 IC50 0.07 μM Cytotoxicity against human A549 cells by MTT assay [PMID: 23566520]
A549 IC50 0.08 μM Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay [PMID: 32650182]
A549 IC50 0.082 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 26725027]
A549 IC50 0.11 μM Antitumor activity against human A549/ATCC cells by SRB method [PMID: 19541483]
A549 IC50 0.3 μM Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay [PMID: 23639650]
A549 IC50 0.8 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 28441581]
A549 IC50 0.8 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 27836197]
A549 IC50 1.75 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 29921475]
A549 IC50 2.75 μM Cytotoxicity against human A549 cells after 48 hrs by MTT assay [PMID: 30108853]
A549 IC50 33.6 nM Cytotoxicity against human A549 after 72 hrs by SRB assay [PMID: 22647222]
A549 IC50 9.13 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 30528976]
Bcap37 IC50 > 20 μM Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay [PMID: 23124210]
Bcap37 IC50 28.1 μM Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay [PMID: 26280921]
Bcap37 IC50 28.1 μM Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay [PMID: 25874331]
Bel-7402 IC50 0.2 μM Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay [PMID: 19715319]
Bel-7402 IC50 0.2 μM Cytotoxicity against human Bel7402 cells by MTT assay [PMID: 23566520]

21 records · Scroll to view more

In Vitro Studies

The growth inhibition of HCPT injections against HepG2 cells: IC50 value: 0.6000 μg/mL. The plates were incubated for 24 h. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Growth inhibition in HepG2 cells

Cell-based study · HepG2 cells [1]

The growth inhibition of HCPT injections against HepG2 cells: IC50 value: 0.6000 μg/mL. The plates were incubated for 24 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
growth inhibition; IC50IC50 HepG2 cells; 24 h: IC50 = 0.6000 μg/mL[1]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Method
The medium was then replaced with 200 μL HCPT-NSps or HCPT injections
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: (S)-10-Hydroxycamptothecin; Compound label in the paper: HYDROXYCAMPTOTHECIN

Evidence for (S)-10-Hydroxycamptothecin as the sodium form reported in the paper, not the free base/neutral form supplied as A11997; no salt equivalence, dose conversion or lot validation.

Material and methods > Materials (S3); Material and methods > Cytotoxicity assay and cellular uptake (S64, S65, S66); Figure 5 legend (S97)

growth inhibition; IC50: growth inhibition; IC50; comparator: HCPT-NSps — Material and methods > Cytotoxicity assay and cellular uptake (S65); Figure 5 legend (S97)

In Vivo Studies

ICR male mice bearing H22 tumors received the compound at 5 mg/kg by intravenous injection through the tail vein. The tumor inhibitory rate was 34.97% relative to the blank control. [1]

Tumor inhibition in tumor-bearing mice

Animal study · ICR male mice; H22 tumor-bearing mice [1]

ICR male mice bearing H22 tumors received the compound at 5 mg/kg by intravenous injection through the tail vein. The tumor inhibitory rate was 34.97% relative to the blank control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor inhibitory rate (TIR)tumor inhibitory rate 34.97%[1]

Conditions shared by the study groups

Route
intravenous injection through the tail vein
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
(S)-10-Hydroxycamptothecin 5 mg/kgThe blank control group received 0.2 mL of normal saline34.97%[1]
(S)-10-Hydroxycamptothecin 5 mg/kg
Model: ICR male mice; H22 tumor-bearing mice
Reported limits: Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: (S)-10-Hydroxycamptothecin; Compound label in the paper: HYDROXYCAMPTOTHECIN

Evidence for (S)-10-Hydroxycamptothecin as the sodium form reported in the paper, not the free base/neutral form supplied as A11997; no salt equivalence, dose conversion or lot validation.

Material and methods > Materials (S3); Material and methods > Animals and tumor cells (S8); Material and methods > In vivo antitumor effect (S76, S77, S78, S82); Table 2 legend (S110); Table 2 (T2.h1, T2.r3)

tumor inhibitory rate (TIR): tumor inhibitory rate (TIR); comparator: The blank control group received 0.2 mL of normal saline — Material and methods > In vivo antitumor effect (S82); Table 2 (T2.h1, T2.r3)

(S)-10-Hydroxycamptothecin 5 mg/kg · Material and methods > In vivo antitumor effect (S78); Table 2 (T2.h1, T2.r3)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 19685-09-7
Applications Topoisomerase
Formula C20H16N2O5
Molecular Weight 364.35
Synonyms HCPT; SN38; Ampule; NSC 107124; HYDROCAMPTOTHECINE; HYDROXYCAMPTOTHECIN
SMILES
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 7 mg/mL (19.21 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Yang L, Hong J, Di J, et al. 10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG1000-HCPT conjugate: high stabilizing efficiency and improved antitumor efficacy. Int J Nanomedicine (2017). PMID: 28553107 DOI: 10.2147/IJN.S134005 Source material

Added to your cart

View Cart Checkout
Loading...